Janux Therapeutics (JANX) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Janux Therapeutics (JANX) over the past year, gaining 55.4% versus a loss of 23.6%. Over five years, JANX leads with a -12.4% price change compared with -31.6% for PCRX. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $1.13 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | PCRX |
|---|---|---|
| Share price | $18.50 | $36.39 |
| Market cap | $1.13B | $1.45B |
| 1-day change | +3.24% | +44.40% |
| YTD return | +34.06% | +40.61% |
| 1-year return | -23.55% | +55.45% |
| 5-year return | -12.45% | -31.60% |
| P/E ratio (TTM) | — | 103.97 |
| Forward P/E | — | 10.52 |
| EPS (TTM) | $-1.64 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.34 | $36.46 |
| 52-week low | $12.12 | $18.80 |
| Distance from 52-week high | -47.65% | -0.19% |
| Analyst consensus | none | buy |
| Avg. price target upside | +95.89% | -17.26% |
| Average volume | 845.95K | 1.03M |
| Shares outstanding | 61.14M | 39.86M |
| Employees | 113 | 825 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed JANX by 79.0 percentage points over the past year.
- The two companies sit in different sectors: Janux Therapeutics in Healthcare and Pacira BioSciences in Health Care.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Healthcare · Biotechnology · 113 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
JANX vs PCRX FAQ
Which is bigger, Janux Therapeutics or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $1.13B for Janux Therapeutics (JANX).
Which stock has performed better over the past year, JANX or PCRX?
PCRX returned +55.45% over the past 12 months, compared with -23.55% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and Pacira BioSciences in the same industry?
No. Janux Therapeutics is in the Healthcare sector, while Pacira BioSciences is in Health Care.